AKTX • NASDAQ
Akari Therapeutics, Plc
$18.27
Stock Details
| Market Cap | 20,911,604 |
|---|---|
| Day Change | 13.13 (255.45%) |
| Volume | 34,043,144 |
| Avg Volume | 703,188 |
| Price Range | 3.015-56.8 |
Overview
| Country | GB |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Financial Overview
| 52 Week High | 56.8 |
|---|---|
| 52 Week High Date | 2025-06-02 |
| 52 Week Low | 3.015 |
| 52 Week Low Date | 2026-05-12 |
| 10D Avg Trading Vol | 4.06144 |
| YTD Price Return Daily | 58.045 |
| MTD Price Return Daily | 238.3271 |
Cash Flow
| TTM/Share | -15.63809 |
|---|---|
| Annual/Share | -0.0012 |
| Quarterly/Share | -0.0007 |
Price-to-Earnings
| Annual Ratio | 0.4422 |
|---|---|
| Quarterly Ratio | 0.4422 |
| TTM |
Earnings Per Share
| Annual | -0.0003 |
|---|---|
| 3Y Growth | |
| 5Y Growth | |
| Quarterly YOY Growth |
Price-to-Book
| Ratio | 0.7382 |
|---|---|
| Annual Ratio | 0.308 |
| TTM | 0.308 |